Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


EMax Endpoint ELISA Microplate Reader

Product Description
The EMax® Endpoint ELISA Microplate Reader from Molecular Devices, one of the pioneers in microplate detection, offers a ruggedly simple approach to dedicated endpoint assays. A staggering mean time between failure (MTBF) of 20,000 hours is achieved by 97 independent and stationary fiber optics so that the microplate remains stationary during the entire reading cycle, reducing the number of moving parts. No optical alignment needed during the lifetime of the instrument!

Through sequential, single-well illumination, 100% of the available light is directed to each well through the optical fibers to achieve linearity to higher optical densities (ODs) and optimal signal-to-noise ratios. At 5 seconds to read a 96-well endpoint assay, the EMax Microplate Reader has both the speed and performance to carry a heavy workload.

The EMax Microplate Reader is capable of reading up to two wavelengths at a time in the visible wavelength spectrum (400nm-750nm), with 4 filter choices included at time of purchase. Additional high-quality filters to supplement your assay wavelength range requirements are available directly from Molecular Devices.
Product EMax Endpoint ELISA Microplate Reader
Company Molecular Devices Product Directory
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Molecular Devices Product Directory
1311 Orleans Drive Sunnyvale, CA 94089-11361 United States

Tel: 1-800-635-5577
Fax: 1-408-548-6439
Email: om@moldev.com



Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.

SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!